NVIDIA Expands Healthcare Footprint with Strategic Partnerships with IQVIA, Illumina, Mayo Clinic, and Arc Institute

NVIDIA Announces New Partnerships at JPM (J.P. Morgan Healthcare Conference) withIQVIA、Illumina、Mayo ClinicAnd Arc InstituteWith the help of NVIDIA AI And accelerated computing technology,Aiming to drive the transformation of the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research, and leveraging agent-based and generative AI to pioneer advanced medical services.

These solutions include AI agents capable of accelerating clinical trials by reducing administrative burdens, AI models that learn from biological instruments to advance drug discovery and digital pathology, and physical AI robots used for surgery, patient monitoring, and management. AI agents, AI instruments, and AI robots will help reduce operational costs in a $3 trillion industry while creating hundreds of billions of dollars in AI industrial opportunities.

NVIDIA Vice President of Healthcare Kimberly Powell stated, "AI provides a rare opportunity for advancements in healthcare and life sciences, offering a range of tools that can help medical institutions detect diseases earlier and develop new therapies more quickly. The combination of NVIDIA's AI and accelerated computing capabilities with the expertise of leading institutions in the industry is expected to usher in a new era of innovation in healthcare and biology, while improving treatment outcomes for patients worldwide."

IQVIA is a global leader in clinical research services, commercial analytics, and healthcare information, dedicated to serving the life sciences and healthcare industries. The organization is leveraging NVIDIA AI Foundry, combined with its deep domain expertise, to build customized foundational models on a data foundation exceeding 64PB. Meanwhile, IQVIA is developing proxy-based AI solutions powered by NVIDIA AI Enterprise software—including NVIDIA NIM™ microservices and NVIDIA Blueprints—to accelerate research, clinical development, and the promotion of new therapies. As an industry leader in the responsible use of AI, IQVIA consistently ensures that its AI-driven capabilities are built on a core foundation of privacy protection, regulatory compliance, and patient safety.

"IQVIA President of Commercial Solutions Bhavik Patel stated, 'This marks a significant step forward in applying AI to healthcare and life sciences. We are excited to combine our industry-leading technology and over a decade of AI expertise with NVIDIA’s advanced AI capabilities to create new solutions powered by AI agents. These AI agents are trained on global healthcare information and optimized for life science workflows. This collaboration will drive our mission to help clients accelerate innovation and bring treatments to market faster.'"

Illumina, a global leader in DNA sequencing and informatics technology, is collaborating with NVIDIA to advance a new generation of genomics research for drug discovery and human health.

Through this collaboration, Illumina will be able to utilize NVIDIA’s accelerated computing and AI toolset in its multi-omics analysis software and workflows. This will enable researchers, pharmaceutical companies, and other customers in the life sciences field to more conveniently analyze the human genome and derive insights from it.

Illumina will provide NVIDIA-accelerated computing-based DRAGEN analysis software within the Illumina Connected Analytics platform. This integration aims to extend the accessibility of DRAGEN to any NVIDIA computing platform globally.

In the past five years, single-cell and spatial genomics have deepened our understanding of cells from an unprecedented perspective, revolutionizing drug discovery models. To further expand the genomics market and drive breakthroughs in target identification, clinical development, and biomarker discovery, NVIDIA and Illumina plan to collaborate on the Illumina Connected Analytics platform to advance multi-omics data analysis and develop new foundational biological models.

The R&D team can more quickly and conveniently leverage rich genomic data by integrating the NVIDIA RAPIDS™ accelerated data science software from the NVIDIA AI Enterprise software platform, the generative AI models of the NVIDIA BioNeMo™ platform along with its fine-tuning capabilities for proprietary datasets, and MONAI for spatial cellular imaging workflows. Illumina will work together with NVIDIA to make these tools available on the Illumina Connected Analytics platform.

"Illumina Chief Technology Officer Steve Barnard stated, 'By combining the power of AI with multi-omics data, we are revolutionizing our understanding of disease. By merging Illumina's expertise in genomics data and analysis with NVIDIA's powerful AI platform, we will empower pharmaceutical and biotechnology companies to unlock transformative insights from their multi-omics data, increasing the success rate of developing life-saving therapies.'"

Pathology is a key method for clinicians to diagnose and determine treatment plans for various types of cancer, as well as other serious and complex health conditions, which has always been a slow and labor-intensive process. The digital pathology platform of Mayo Clinic, supported by autonomous robotic laboratories and advanced imaging technologies, possesses a rich and unique dataset containing 20 million whole-slide images and 10 million associated patient records, providing the foundation for creating foundational models.

Mayo Clinic and NVIDIA to Significantly Accelerate the Development of Next-Generation Pathology Foundation Models. Mayo Clinic plans to deploy the newly launched NVIDIA DGX™ Blackwell system, which is based on the NVIDIA Blackwell architecture and provides 1.4TB of GPU memory per system, making it highly suitable for handling whole-slide datasets in digital pathology. Additionally, Mayo Clinic will adopt the NVIDIA medical imaging platform MONAI.

Mayo Clinic and NVIDIA's collaboration aims to lay the foundation for AI applications in future drug discovery, personalized diagnostics, and treatment. The two parties will continue to expand their partnership, combining Mayo Clinic's clinical and AI expertise with NVIDIA's Cosmos Nemotron vision-language model and NIM microservices to deliver more personalized healthcare experiences and predictive, efficient treatment strategies.

Arc Institute is a research institution located in Palo Alto, California, focusing on the intersection of biology and machine learning. The institute is collaborating with NVIDIA to develop and share powerful AI models and tools to drive biomedical discoveries.

Researchers in biology and machine learning at Arc are collaborating with engineers from NVIDIA to unlock the potential of foundational models in biology, enabling their versatility across different biomolecular levels such as DNA, RNA, and proteins. This collaboration aims to advance the application of these models in various fields, including drug discovery, synthetic biology of varying complexity, disease research, and evolutionary studies.

As part of the collaboration, NVIDIA provided Arc Institute with expertise in large-scale model development, as well as the NVIDIA BioNeMo platform running on NVIDIA DGX Cloud for accessible and optimized training. Additionally, NVIDIA offered the NVIDIA NIM microservices and Blueprints.

In recent years, NVIDIA has gradually placed significant emphasis on healthcare and listed it as one of the key directions for NVIDIA's future strategic development. This comes as no surprise,AI is fundamentally transforming healthcare and is expected to achieve biological advancements within the next decade that were originally projected to take the entire 21st century, potentially curing rare diseases.

AsOne of the largest providers of AI computing power, NVIDIA has been continuously improving its layout in AI healthcare. The recent collaboration with four leading enterprises and institutions in the medical field is its latest move. VCBeat will continue to follow up on what further plans this AI giant has for the future of healthcare.